Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Gilliland

Showing results (51-60 of 182) with videos related to

Pageof 19
Sort By:
Blood|January 5, 2002
FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant modelLouise M Kelly, Qing Liu, Jeffrey L Kutok, et al.
Blood|February 10, 2009
Skewing of X-inactivation ratios in blood cells of aging women is confirmed by independent methodologiesLambert Busque, Yves Paquette, Sylvie Provost, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 21, 2005
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformationXiaohui Lu, Ross Levine, Wei Tong, et al.
Blood|March 26, 2005
Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412Joseph D Growney, Jennifer J Clark, Jennifer Adelsperger, et al.
Blood|January 26, 2006
X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesisRoss L Levine, Claude Belisle, Martha Wadleigh, et al.
Blood|April 22, 2006
Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITDJennifer L Rocnik, Rachel Okabe, Jin-Chen Yu, et al.
British Journal of Haematology|November 17, 2006
Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over timeTerra L Lasho, Animesh Pardanani, Rebecca F McClure, et al.
Blood|November 25, 2003
The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemiaJan Cools, Hilmar Quentmeier, Brian J P Huntly, et al.
Cancer Cell|July 19, 2002
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412Ellen Weisberg, Christina Boulton, Louise M Kelly, et al.
Cancer Research|September 18, 2004
Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemiaJan Cools, Nicole Mentens, Pascal Furet, et al.
Pageof 19

Showing results (51-60 of 182) with videos related to

Sort By:
Pageof 19
Blood|January 5, 2002
FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant modelLouise M Kelly, Qing Liu, Jeffrey L Kutok, et al.
Blood|February 10, 2009
Skewing of X-inactivation ratios in blood cells of aging women is confirmed by independent methodologiesLambert Busque, Yves Paquette, Sylvie Provost, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 21, 2005
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformationXiaohui Lu, Ross Levine, Wei Tong, et al.
Blood|March 26, 2005
Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412Joseph D Growney, Jennifer J Clark, Jennifer Adelsperger, et al.
Blood|January 26, 2006
X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesisRoss L Levine, Claude Belisle, Martha Wadleigh, et al.
Blood|April 22, 2006
Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITDJennifer L Rocnik, Rachel Okabe, Jin-Chen Yu, et al.
British Journal of Haematology|November 17, 2006
Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over timeTerra L Lasho, Animesh Pardanani, Rebecca F McClure, et al.
Blood|November 25, 2003
The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemiaJan Cools, Hilmar Quentmeier, Brian J P Huntly, et al.
Cancer Cell|July 19, 2002
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412Ellen Weisberg, Christina Boulton, Louise M Kelly, et al.
Cancer Research|September 18, 2004
Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemiaJan Cools, Nicole Mentens, Pascal Furet, et al.
Pageof 19